Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
by on Tuesday, January 24th, 2012 | No Comments
Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsor: Bristol-Myers Squibb
Not yet recruiting – verified January 2012
Read the rest here: Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab